Merck Animal Health Partners and AVC Foundation to award scholarships to future bovine veterinarians The Fence Post
Original post:
Merck Animal Health Partners and AVC Foundation to award scholarships to future bovine veterinarians - The Fence Post
Teamwork Makes the Dream Work: The CVM continues push to hire innovative faculty Clemson News
Excerpt from:
Teamwork Makes the Dream Work: The CVM continues push to hire innovative faculty - Clemson News
Kays Foundation Commits More than $500K to College of Veterinary Medicine NEA Report
Original post:
Kays Foundation Commits More than $500K to College of Veterinary Medicine - NEA Report
Kays Foundation commits more than $500,000 to Arkansas State University College of Veterinary Medicine Arkansas Online
A Crisis in the Veterinary World The Plaid Horse
Visit link:
A Crisis in the Veterinary World - The Plaid Horse
Project Street Vet and Sheriffs Office Unite to Aid Homeless Pet Owners in Oceanside Angels in Medicine
Read the original:
Project Street Vet and Sheriffs Office Unite to Aid Homeless Pet Owners in Oceanside - Angels in Medicine
LSU Vet Med pays tribute to pets and their people with giant purple and gold sculpture The Advocate
Read this article:
LSU Vet Med pays tribute to pets and their people with giant purple and gold sculpture - The Advocate
Just one thing: Allocating practice owner time productively American Veterinary Medical Association
The ideal place to take reptiles pulse DVM 360
Excerpt from:
The ideal place to take reptiles pulse - DVM 360
6 veterinarian team at McAfee Animal Hospital bring a loving family atmosphere to the workplace Valpo.Life
Careers in Agriculture: Love of working with animals develops into veterinarian career Agri-News
See the original post:
Careers in Agriculture: Love of working with animals develops into veterinarian career - Agri-News
Small Animal Specialist Hospital (SASH) Vets Australia: Heroes of The Pet World Catster
The rest is here:
Small Animal Specialist Hospital (SASH) Vets Australia: Heroes of The Pet World - Catster
HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
More:
Celldex Therapeutics to Present at Upcoming Investor Conferences
TORONTO and HAIFA, Israel, Sept. 12, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce its participation in a series of prestigious conferences this October. These events will showcase the Company’s advancements in exosome therapy, reinforce its commitment to driving innovation in regenerative medicine, and increase visibility with major pharmaceutical companies.
Continued here:
NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
BEDFORD, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to its newly appointed Director, IT Cybersecurity, Russell Isaacs. The awards were made as inducements material to Mr. Isaacs’ acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Go here to see the original:
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse population 23andMe, National Human Genome Research Institute, and Johns Hopkins University conducted collaborative research that studied sickle cell trait in a diverse population
NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company, has successfully completed the previously announced acquisition of Atwater Brewery, from Molson Coors Beverage Company (“Molson Coors”) (NYSE: TAP).
Read this article:
Tilray Brands Completes Acquisition of Atwater Brewery From Molson Coors Beverage Company
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 10:20 a.m. ET in New York.
Go here to read the rest:
Generation Bio to Present at the 2024 Cantor Global Healthcare Conference
Advanced PCR-based screening platform deployed nationwide across 30 laboratories provides new capabilities to detect malaria, HIV, HCV, and HBV in blood donations // Advanced capabilities support epidemiological surveillance of ongoing dengue outbreak in Brazil with unique chemistry developed by QIAGEN and Bio-Manguinhos/Fiocruz // Partnership highlights QIAGEN’s commitment to custom and OEM solutions, technology transfer and long-term support Advanced PCR-based screening platform deployed nationwide across 30 laboratories provides new capabilities to detect malaria, HIV, HCV, and HBV in blood donations // Advanced capabilities support epidemiological surveillance of ongoing dengue outbreak in Brazil with unique chemistry developed by QIAGEN and Bio-Manguinhos/Fiocruz // Partnership highlights QIAGEN’s commitment to custom and OEM solutions, technology transfer and long-term support
Here is the original post:
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced a reduction in its workforce to focus on the clinical development of CD388, the Company’s novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce.
Continued here:
Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388